NCT00636441View on ClinicalTrials.gov

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Early-Stage Breast Cancer
Interventions
DRUG

Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)

Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Duke University

OTHER

NCT00636441 - Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer | Biotech Hunter | Biotech Hunter